左旋多巴与脱羧酶抑制剂：其临床药理学及在帕金森病治疗中的应用综述 - Suppr

Suppr

超能文献

Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

作者信息

Pinder R M, Brogden R N, Sawyer P R, Speight T M, Avery G S

出版信息

Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.

DOI:10.2165/00003495-197611050-00001

PMID:782834

Abstract

摘要

相似文献

Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.左旋多巴与脱羧酶抑制剂：其临床药理学及在帕金森病治疗中的应用综述

Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.

[Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].[帕金森病患者在左旋多巴脱羧酶抑制剂治疗期间的体感诱发电位]

Neurol Neurochir Pol. 1977 Jan-Feb;11(1):73-80.

Comparison of levodopa with carbidopa or benserazide in parkinsonism.左旋多巴与卡比多巴或苄丝肼治疗帕金森病的比较。

Lancet. 1976 Aug 21;2(7982):381-4. doi: 10.1016/s0140-6736(76)92403-x.

[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].左旋多巴与外周多巴脱羧酶抑制剂联合治疗帕金森病——13例临床病程及血清/多巴和多巴胺水平

Rinsho Shinkeigaku. 1976 Jul 1;16(7):511-9.

Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.用外周脱羧酶抑制剂卡比多巴和左旋多巴治疗帕金森病。

Med Ann Dist Columbia. 1974 Dec;43(12):587-91.

[CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].[CB 154治疗帕金森病。与左旋多巴和脱羧酶抑制剂联合使用的结果]

Acta Neurol (Napoli). 1976 Jul-Aug;31(4):479-48.

Levodopa with benserazide or carbidopa in Parkinson disease.左旋多巴与苄丝肼或卡比多巴治疗帕金森病。

Neurology. 1979 Dec;29(12):1584-9. doi: 10.1212/wnl.29.12.1584.

Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.用息宁或美多芭治疗帕金森病。一项对照多中心试验。

Acta Neurol Scand. 1976 May;53(5):376-85. doi: 10.1111/j.1600-0404.1976.tb04355.x.

[Clinical significance of cramps of the lower extremities in patients with parkinsonism].[帕金森病患者下肢痉挛的临床意义]

Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1985 Aug;18(4):217-8.

[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].左旋多巴加脱羧酶抑制剂（卡比多巴、苄丝肼）联合治疗帕金森病（作者译）

Wien Klin Wochenschr. 1979 May 11;91(10):332-7.

引用本文的文献

Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging.18F-DOPA正电子发射断层显像（PET）成像的正常生物分布模式及生理变异

Nucl Med Commun. 2013 Dec;34(12):1141-9. doi: 10.1097/MNM.0000000000000008.

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.帕金森病动物模型：新型治疗方法的来源和疾病病因的线索。

Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x.

Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.帕金森病中的刺蒺藜豆：一项双盲临床与药理学研究。

J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.

Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients.

Eur J Pediatr. 1996 Jul;155 Suppl 1:S74-7. doi: 10.1007/pl00014256.

Pharmacokinetic optimisation in the treatment of Parkinson's disease.帕金森病治疗中的药代动力学优化

Clin Pharmacokinet. 1996 Jun;30(6):463-81. doi: 10.2165/00003088-199630060-00004.

A risk-benefit assessment of drugs used in the management of Parkinson's disease.帕金森病治疗用药的风险效益评估

Drug Saf. 1994 Aug;11(2):94-103. doi: 10.2165/00002018-199411020-00004.

Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria.

J Inherit Metab Dis. 1994;17(3):349-52. doi: 10.1007/BF00711827.

Fixed combination drug therapy.固定复方药物疗法。

Drugs. 1982 Jun;23(6):462-80. doi: 10.2165/00003495-198223060-00003.

Intestinal absorption of levodopa in man.左旋多巴在人体肠道的吸收情况。

Eur J Clin Pharmacol. 1983;25(1):69-72. doi: 10.1007/BF00544017.

The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.化学结构新颖的多巴胺能激动剂西拉丁多（AY - 27,110）对6 - 羟基多巴胺损伤大鼠和未损伤大鼠的长期比较效应。

Psychopharmacology (Berl). 1985;85(4):405-9. doi: 10.1007/BF00429654.

本文引用的文献

Drug-induced changes of extracerebral dopa metabolism in man.

Arch Neurol. 1969 Feb;20(2):187-90. doi: 10.1001/archneur.1969.00480080087010.

Cardiovascular effects of levodopa.

Clin Pharmacol Ther. 1971 Mar-Apr;12(2):376-82. doi: 10.1002/cpt1971122part2376.

Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation.通过抑制脑外左旋多巴脱羧作用选择性提高脑内多巴胺水平。

Clin Pharmacol Ther. 1971 Mar-Apr;12(2):344-52. doi: 10.1002/cpt1971122part2344.

Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor.

Clin Pharmacol Ther. 1971 Mar-Apr;12(2):212-7. doi: 10.1002/cpt1971122part1212.

The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary.

Neurology. 1970 Dec;20(12):46-59.

Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.左旋多巴单独及与脑外脱羧酶抑制剂联合应用对血压及某些心血管反射的影响。

Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740-6. doi: 10.1002/cpt1970115740.

Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.脱羧酶抑制剂对L(-)-多巴某些中枢作用的增强和抑制

J Pharmacol Exp Ther. 1970 Apr;172(2):406-15.

[The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].

Experientia. 1970 Apr 15;26(4):381-3. doi: 10.1007/BF01896900.

Aromatic amino acids and modification of parkinsonism.芳香族氨基酸与帕金森病的修饰

N Engl J Med. 1967 Feb 16;276(7):374-9. doi: 10.1056/NEJM196702162760703.

Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).α-甲基多巴肼（MK-486）对帕金森病左旋多巴治疗的改良作用

Trans Am Neurol Assoc. 1971;96:55-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验